Margaret Mccartney. GLP1 en mundo real.

 Los aGLP1 en el mundo real:

- Una minoría de pacientes que iniciaron AR de GLP-1 lograron una pérdida de peso de ≥5% al año. - Atención a la pérdida muscular, se observó una disminución en la masa libre de grasa. Vía

@mgtmccartney

.

https://margaretmccartney.com/

NICE https://www.nice.org.uk/guidance/indevelopment/gid-ta10765

NEJM Step1 https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

Step 1 extension https://pubmed.ncbi.nlm.nih.gov/35441470/

Step 5 trial (2 years)

https://www.nature.com/articles/s41591-022-02026-4#:~:text=Safety%20and%20tolerability,placebo%20group%20(Table%203).

Weight loss outcomes

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2796491#:~:text=The%20Semaglutide%20Treatment%20Effect%20in,for%20the%20treatment%20of%20obesity.&text=In%20large%20RCTs%2C%20patients%20receiving,their%20weight%20by%20week%2028.

Real world outcomes in type 2 diabetes

https://drc.bmj.com/content/10/1/e002517

on side effects

https://pubmed.ncbi.nlm.nih.gov/32628589/

Semaglutide: ¿Deberían los medios frenar su entusiasmo?

https://www.bmj.com/